<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">

Mark Weinstein


Recent Posts

Champions Oncology Reports Record Quarterly Revenue of $5.2 Million

Dec 12, 2017 11:08:16 AM / by Mark Weinstein

Quarterly operating profit driven by double-digit revenue growth

Hackensack, NJ – December 7, 2017 – Champions Oncology, Inc. (Nasdaq : CSBR) engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second fiscal quarter and six months ended October 31, 2017.

Read More →

Champions Oncology announces $2 million award from the National Cancer Institute (NCI) to develop and evaluate prostate cancer PDX models

Sep 26, 2017 2:53:02 PM / by Mark Weinstein

HACKENSACK, NJ - September 26, 2017 - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the signing of a competitive contract through the government’s Small Business Innovation Research (SBIR) program. The contract is in response to Topic 355 – Cell and Animal-Based Models to Advance Cancer Ethnic Health Disparity Research. Champions’ direct-to-Phase II proposal, entitled “Metastatic Prostate Cancer Patient Derived Xenograft Modeling; A New Operating Paradigm”. The contract is a 2-year, $2 million project.  Champions’ network of collaborating sites will contribute to this project.

Read More →

Champions Oncology announces publication highlighting clinical correlation between patient-derived xenograft (PDX) model responses and patient responses to oncology therapies

Sep 18, 2017 8:42:51 AM / by Mark Weinstein

HACKENSACK, NJ - September 18, 2017 - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the publication entitled “Patient-derived xenografts (PDX) effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors” in the journal Annals of Oncology.   Annals of Oncology is published by the European Society for Medical oncology (ESMO), the leading European professional organization for medical oncology in Europe.  Building on earlier clinical correlation data, this study further demonstrates that PDX models accurately predict patient response to oncology drugs with remarkable 85% positive predictive value.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $5 Million

Sep 15, 2017 12:37:57 PM / by Mark Weinstein

37.1% year-over-year revenue increase

Hackensack, NJ – September 14, 2017 – Champions Oncology, Inc. (Nasdaq : CSBR) engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2017.

Read More →

Champions Oncology Announces Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of Patient-Derived Xenograft (PDX) Models

Aug 21, 2017 1:22:51 PM / by Mark Weinstein

HACKENSACK, NJ - August 21, 2017 /PRNewswire/ - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a strategic collaboration with AstraZeneca to develop novel cohorts of PDX models. These models will be used in AstraZeneca’s oncology R&D programs in breast and lung cancer, in addition to being added to Champions’ existing TumorGraft bank for translational oncology research for academic and industry customers. Champions’ global network of collaborating sites will be leveraged to support this multi-year initiative.

Read More →
Content not found